AB-CHMINACA is an indazole-based synthetic cannabinoid. It acts as a potent agonist for the cannabinoid receptors which produces subjective effects somewhat similar to that of cannabis. It was developed by Pfizer and disclosed in a 2009 patent as a potential analgesic medication, but was never pursued for human use.
The physiological and toxicological properties of this compound are not known. This product is intended for forensic and research applications.
POWER: light | normal | strong | very strong
Systematic (IUPAC) name: N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)indazole-3-carboxamide
CAS Number: 1185887-21-1
Molar mass: 356.46 g/mol